胜肽組織化學診斷法

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

102137765

專利證號

I 491881

專利獲證名稱

胜肽組織化學診斷法

專利所屬機關 (申請機關)

國立臺灣大學

獲證日期

2015/07/11

技術說明

在之前我們利用噬菌體展示胜肽庫(phage-displayed random peptide library)與鼻咽癌細胞(NPC cells)作用而找出一特殊胜肽,並將之用來做標靶化療去治療鼻咽癌、乳癌、肝癌及胰臟癌.結果發現此胜肽有類似對NPC的療效. 此外, 我們也用L-P 連結氧化鐵之奈米顆粒去做MRI,以觀察在體內腫瘤的影像,而得不錯的結果.由於在之前的研究中, 發現另一種特殊的胜肽PC5-2可專與非小細胞肺癌結合.因此,本計畫要做試驗比較用L-胜肽及PC5-2-胜肽去觀察是否對肺癌及大腸癌有相似的療效,是否也能用MRI去做影像分析,是否也能用所發明的胜肽組織化學法去預測其療效.希望在此臨床前之試驗結果,能澄清證明L-胜肽是一具有多功能的胜肽,扮演一重要標靶化療及分子影像分析功能,並能以其胜肽組織化學法去預測其用於化療之療效. Previously we have demonstrated that tumor-specific peptide-targeted chemotherapy is superior to conventional chemotherapy for the treatment of nasopharyngeal carcinoma (NPC) in the animal model. In that study, using a phage-displayed random peptide library we have identified a novel 12-mer peptide (L-peptide) from a NPC cell line. In vitro this peptide can bind specifically to the cell surfaces of most NPC cell lines and biopsy specimens; but not in normal organs; the L-peptide-linked liposome carried doxorubicin (L-P-Lipo-Dox) not only causes marked cytotoxicity of NPC cells in vitro and in vivo, it also suppresses markedly the xenograft growth of other cancers such as liver and pancreatic cancers in SCID mice with minimal adverse effect. In addition, using the same method, we have also found a specific peptide (PC5-52 peptide) which can bind cancer vascular endothelia.

備註

連絡單位 (專責單位/部門名稱)

產學合作總中心

連絡電話

33669945

網址